Sino Biopharmaceutical Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA

Reuters

Sep 22

<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA

Sino Biopharmaceutical Limited has announced that their Investigational New Drug (IND) application for TQF3250 capsules, a "GLP-1 receptor agonist," has been accepted by the National Medical Products Administration (NMPA) of China. TQF3250, an innovative drug designed for the treatment of type 2 diabetes, is an orally administered small-molecule that effectively promotes insulin secretion. This development marks a significant step forward in providing a convenient and effective treatment option for type 2 diabetes patients. Currently, only one other orally administered GLP-1 receptor agonist has been approved globally. Sino Biopharmaceutical Limited aims to expedite the clinical development of TQF3250 following this regulatory acceptance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569698207"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569698207\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569698207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569698207","market":"fut","top_or_hot":-1,"title":"Sino Biopharmaceutical Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a> Limited has announced that their Investigational New Drug (IND) application for TQF3250 capsules, a \"GLP-1 receptor agonist,\" has been accepted by the National Medical Products Administration (NMPA) of China. TQF3250, an innovative drug designed for the treatment of type 2 diabetes, is an orally administered small-molecule that effectively promotes insulin secretion. This development marks a significant step forward in providing a convenient and effective treatment option for type 2 diabetes patients. Currently, only one other orally administered GLP-1 receptor agonist has been approved globally. Sino Biopharmaceutical Limited aims to expedite the clinical development of TQF3250 following this regulatory acceptance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-22 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SBMFF\">Sino Biopharmaceutical</a> Limited has announced that their Investigational New Drug (IND) application for TQF3250 capsules, a \"GLP-1 receptor agonist,\" has been accepted by the National Medical Products Administration (NMPA) of China. TQF3250, an innovative drug designed for the treatment of type 2 diabetes, is an orally administered small-molecule that effectively promotes insulin secretion. This development marks a significant step forward in providing a convenient and effective treatment option for type 2 diabetes patients. Currently, only one other orally administered GLP-1 receptor agonist has been approved globally. Sino Biopharmaceutical Limited aims to expedite the clinical development of TQF3250 following this regulatory acceptance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL7b4Vkx:1","article_id":"2569698207","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569698207","pubTimestamp":1758530904,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sino Biopharmaceutical Limited has announced that their Investigational New Drug  application for TQF3250 capsules, a \"GLP-1 receptor agonist,\" has been accepted by the National Medical Products Administration  of China. TQF3250, an innovative drug designed for the treatment of type 2 diabetes, is an orally administered small-molecule that effectively promotes insulin secretion. This development marks a significant step forward in providing a convenient and effective treatment option for type 2 diabetes patients. Currently, only one other orally administered GLP-1 receptor agonist has been approved globally. Sino Biopharmaceutical Limited aims to expedite the clinical development of TQF3250 following this regulatory acceptance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓"},"translate_title":"中国生物制药有限公司TQF3250胶囊“GLP-1受体激动剂”的IND申请获国家药监局受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharmaceutical Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA\n    \n\nSino Biopharmaceutical Limited has announced that their Investigational New Drug (IND) application for TQF3250 capsules, a \"GLP-1 receptor agonist,\" has been accepted by the National Medical Products Administration (NMPA) of China. TQF3250, an innovative drug designed for the treatment of type 2 diabetes, is an orally administered small-molecule that effectively promotes insulin secretion. This development marks a significant step forward in providing a convenient and effective treatment option for type 2 diabetes patients. Currently, only one other orally administered GLP-1 receptor agonist has been approved globally. Sino Biopharmaceutical Limited aims to expedite the clinical development of TQF3250 following this regulatory acceptance.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}